GlassScriptPhysician profile
Beth A Mewis
NPI 1164469136
$322.19
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $97.16 | 2019 | |
| Pfizer INC. | $62.94 | 2019 | |
| Intuitive Surgical, INC. | $31.13 | 2019 | |
| Glaxosmithkline, LLC. | $25.00 | 2019 | |
| Merck Sharp & Dohme LLC | $23.37 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.66 | 2019 | |
| Shire North American Group INC | $12.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Mewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.